The global ibuprofen market was valued at USD 1,146.2 Million in 2019 and is projected to reach USD 1,436.8 Million by 2027, expanding at a CAGR of 2.7% during the forecast period. Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID), which is considered as one of the safest conventional by spontaneous adverse drug reaction reporting systems in the UK. It is a kind of medication having analgesic, anti-inflammatory effects, antiplatelet effect, and fever-reducing properties that can be used for conditions such as headache, toothache, fever, back pains, arthritis, minor injuries, and menstrual cramps. It works by blocking the body’s production of certain natural substance such as prostaglandins, which are released by the body in response to an illness or an injury. Prostaglandins results in inflammation, pain, swelling, or fever in a human body. The World Health Organization (WHO) considers ibuprofen in the list of minimum medical needs for a basic healthcare system.
Market Dynamics
The market is driven by several advantages that the ibuprofen drug offers such as rapid result. Ibuprofen is considered to be essential in the treatment of neurodegenerative diseases. Furthermore, the continuous rising incidence of menstrual cramps (dysmenorrhea), osteoarthritis, rheumatoid arthritis, juvenile idiopathic arthritis, and various types of pains and aches. Additionally, ibuprofen is an over the counter (OTC) drug making it easily accessible and available for usage among the end-users. This is resulting in the expansion of the global ibuprofen market.
Get Exclusive Sample Report @ https://growthmarketreports.com/request-sample/94
Definitions
By Types
USP: USP abbreviation of United States Pharmacopeia, is an official pharmacopeia of the US, which was established in 1820. The pharmacopeia contains set of legally recognized standards of identity, strength, quality, purity, packaging, and labeling for drug substances, dosage forms, and other therapeutic products, including nutritionals and dietary supplements. According to, National Institutes of Health (NIH), Ibuprofen Tablets, USP comprise the active ingredient ibuprofen, which is propionic acid. Ibuprofen is a white powdered drug having melting point between 74°C and 77°C, that is to some extent soluble in water and readily soluble in organic solvents that includes ethanol and acetone. The ibuprofen tablets and USP are available in 400mg, 600mg, and 800mg tablets for the purpose of oral administration.
EP: The European Pharmacopoeia (EP) is a major regional pharmacopoeia that provides standards across the pharmaceutical industry in Europe for quality control of the medicines while also checking the quality of the constituents used to manufacture the drugs. According to the European pharmacopoeia, ibuprofen is white or almost white, crystalline powder or colorless crystals that are practically insoluble in water, while easily soluble in acetone, methanol and in methylene chloride. It dissolves in dilute solutions of carbonates and alkali hydroxides.
Regional Outlook
In terms of regions, the market is fragmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is a promising region for the market. The region constituted around one third share of the market in 2019. The market in the region is projected to expand at a substantial CAGR during the forecast period. Increasing population and rising cancer ailments in the region are major factors the ibuprofen market in Asia Pacific. The market in Asia Pacific is projected to expand at a CAGR of approximately 3.0% due growing prevalence of cardiovascular diseases in the region.
For Any Questions On This Report: https://growthmarketreports.com/enquiry-before-buying/94
Competitive Landscape
Key players in the market include BASF SE, Granules India Limited (Granules Biocause), IOL Chemicals and Pharmaceuticals Limited., SI Group, Inc., Strides Pharma Science Limited., Xinhua Pharm, and Zhejiang Hisoar Pharmaceutical Co.,LTD. These companies are considered manufacturers of Ibuprofen based on their revenue, research development (R&D) activities, regional presence, and supply chain management system.The players are adopting key strategies such as acquisition, and geographical expansion where potential opportunity for the Ibuprofen extraction is added in the company’s capacity.For instance, in 2017, BASF announced plans to invest around 200 million euros (USD 232.7 million) in a new ibuprofen plant at its headquarters in Ludwigshafen in Germany and to expand the Bishop site’s production capacity. The new facility in Germany was scheduled to come online in 2021.In 2018, Xinhua Pharma acquired three ibuprofen applications from AiPing Pharmaceutical, Inc. the later company retained sales and distribution rights in the U.S. AiPing Pharmaceutical, Inc. is a US-based pharmaceutical company, engaged in the development, manufacturing, and distribution of pharmaceutical products.About Growth Market Reports:
GMR provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Industry Intelligence Solutions”. GMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain. Our key analysis segments, though not restricted to the same, include market entry strategies, market size estimations, market trend analysis, market opportunity analysis, market threat analysis, market growth/fall forecasting, primary interviews, secondary research & consumer surveys.
Contact:
Growth Market Reports
Phone: +1 909 414 1393
Email: [email protected]
Web: https://growthmarketreports.com
0
Sign in to leave a comment.